The genetics of diabetes and its complications in older adults

Geriatric Diabetes

Volumn , Issue , 2007, Pages 11-27

  Walston, Jeremy D ^a   Silver, Kristi D ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84992748711     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (191)

1. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140(11): 945-950.
2. Okoro CA, Denny CH, Greenlund KJ, et al. Risk factors for heart disease and stroke among diabetic persons, by disability status. J Diabetes Complicat 2005; 19(4): 201-206.
3. Wray LA, Ofstedal MB, Langa KM, Blaum CS. The effect of diabetes on disability in middle-aged and older adults. J Gerontol A Biol Sci Med Sci 2005; 60(9): 1206-1211.
4. Das SK, Elbein SC. The genetic basis of type 2 diabetes. Cellscience 2006; 2(4): 100-131.
5. Sabra M, Silver KD, Shuldiner AR. Candidate genes for type 2 diabetes. In: LeRoth D, Olefsky JM, Taylor SI, eds. In: Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott, 2004: 1003-1012.
6. Zamboni M, Mazzali G, Zoico E, et al. Health consequences of obesity in the elderly: a review of four unresolved questions. Int J Obes (Lond) 2005; 29(9): 1011-1029.
7. Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981; 20(2): 87-93.
8. Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance-a population-based twin study. Diabetologia 1999; 42(2): 139-145.
9. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD. Concordance for type 2 (noninsulin- dependent) diabetes mellitus in male twins. Diabetologia 1987; 30(10): 763-768.
10. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000; 49(12): 2201-2207.
11. Huang QY, Cheng MR, Ji SL. Linkage and association studies of the susceptibility genes for type 2 diabetes. Yi Chuan Xue Bao 2006; 33(7): 573-589.
12. Zacharova J, Chiasson JL, Laakso M. The common polymorphisms [single nucleotide polymorphism (SNP) +45 and SNP +276] of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2005; 54(3): 893-899.
13. Kretowski A, Gugala K, Okruszko A, Wawrusiewicz-Kurylonek N, Gorska M. Single nucleotide polymorphisms in exon 3 of the adiponectin gene in subjects with type 2 diabetes mellitus. Rocz Akad Med Bialymst 2005; 50: 148-150.
14. Stumvoll M, Tschritter O, Fritsche A, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 2002; 51(1): 37-41.
15. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002; 51(7): 2325-2328.
16. Vasseur F, Helbecque N, Lobbens S, et al. Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia 2005; 48(5): 892-899.
17. Sakura H, Wat N, Horton V, Millns H, Turner RC, Ashcroft FM. Sequence variations in the human Kir6.2 gene, a subunit of the β-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia 1996; 39: 1233-1236.
18. Hani EH, Boutin P, Durand E, et al. Missense mutations in the pancreatic islet β cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia 1998; 41(12): 1511-1515.
19. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52(2): 568-572.
20. van Dam RM, Hoebee B, Seidell JC, Schaap MM, de Bruin TW, Feskens EJ. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabet Med 2005; 22(5): 590-598.
21. Florez JC, Burtt N, de Bakker PI, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004; 53(5): 1360-1368.
22. Hansen T, Echwald SM, Hansen L, et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998; 47(4): 598-605.
23. Inoue H, Ferrer J, Welling CM, et al. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 1996; 45: 825-831.
24. Laukkanen O, Pihlajamaki J, Lindstrom J, et al. Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish diabetes prevention study. J Clin Endocrinol Metab 2004; 89(12): 6286-6290.
25. Walston J, Silver K, Bogardus C, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β-3-adrenergic-receptor gene. N Engl J Med 1995; 333(6): 343-347.
26. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the β-3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333(6): 348-351.
27. Allison DB, Heo M, Faith MS, Pietrobelli A. Meta-analysis of the association of the Trp64Arg polymorphism in the β-3 adrenergic receptor with body mass index. Int J Obes Relat Metab Disord 1998; 22(6): 559-566.
28. Walston J, Silver K, Hilfiker H, et al. Insulin response to glucose is lower in individuals homozygous for the Arg 64 variant of the β-3-adrenergic receptor. J Clin Endocrinol Metab 2000; 85(11): 4019-4022.
29. Walston J, Andersen RE, Seibert M, et al. Arg64 β-(3)-adrenoceptor variant and the components of energy expenditure. Obes Res 2003; 11(4): 509-511.
30. Perfetti R, Hui H, Chamie K, et al. Pancreatic β-cells expressing the Arg64 variant of the β-(3)- adrenergic receptor exhibit abnormal insulin secretory activity. J Mol Endocrinol 2001; 27(2): 133-144.
31. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26(2): 163-175.
32. Baier LJ, Permana PA, Traurig M, et al. Mutations in the genes for hepatocyte nuclear factor (HNF)-1α, -4α, -1β, and -3β; the dimerization cofactor of HNF-1; and insulin promoter factor 1 are not common causes of early-onset type 2 diabetes in Pima Indians. Diabetes Care 2000; 23(3): 302-304.
33. Malecki MT, Moczulski DK, Klupa T, et al. Homozygous combination of calpain 10 gene haplotypes is associated with type 2 diabetes mellitus in a Polish population. Eur J Endocrinol 2002; 146(5): 695-699.
34. Orho-Melander M, Klannemark M, Svensson MK, Ridderstrale M, Lindgren CM, Groop L. Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels. Diabetes 2002; 51(8): 2658-2664.
35. Garant MJ, Kao WH, Brancati F, et al. SNP43 of CAPN10 and the risk of type 2 diabetes in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 2002; 51(1): 231-237.
36. Horikawa Y, Oda N, Yu L, et al. Genetic variations in calpain-10 gene are not a major factor in the occurrence of type 2 diabetes in Japanese. J Clin Endocrinol Metab 2003; 88(1): 244-247.
37. Cassell PG, Jackson AE, North BV, et al. Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians. Diabetes 2002; 51(5): 1622-1628.
38. Tsai HJ, Sun G, Weeks DE, et al. Type 2 diabetes and three calpain-10 gene polymorphisms in Samoans: no evidence of association. Am J Hum Genet 2001; 69(6): 1236-1244.
39. Bosque-Plata L, Aguilar-Salinas CA, Tusie-Luna MT, et al. Association of the calpain-10 gene with type 2 diabetes mellitus in a Mexican population. Mol Genet Metab 2004; 81(2): 122-126.
40. Rasmussen SK, Urhammer SA, Berglund L, et al. Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin resistance, and impaired acute insulin secretion among Scandinavian Caucasians. Diabetes 2002; 51(12): 3561-3567.
41. Fingerlin TE, Erdos MR, Watanabe RM, et al. Variation in three single nucleotide polymorphisms in the calpain-10 gene not associated with type 2 diabetes in a large Finnish cohort. Diabetes 2002; 51(5): 1644-1648.
42. Elbein SC, Chu W, Ren Q, et al. Role of calpain-10 gene variants in familial type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87(2): 650-654.
43. Daimon M, Oizumi T, Saitoh T, et al. Calpain 10 gene polymorphisms are related, not to type 2 diabetes, but to increased serum cholesterol in Japanese. Diabetes Res Clin Pract 2002; 56(2): 147-152.
44. Xiang K, Fang Q, Zheng T, et al. The impact of calpain-10 gene combined-SNP variation on type 2 diabetes mellitus and its related metabolic traits. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001; 18(6): 426-430.
45. Evans JC, Frayling TM, Cassell PG, et al. Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 2001; 69(3): 544-552.
46. Hegele RA, Harris SB, Zinman B, Hanley AJ, Cao H. Absence of association of type 2 diabetes with CAPN10 and PC-1 polymorphisms in Oji-Cree. Diabetes Care 2001; 24(8): 1498-1499.
47. Song Y, Niu T, Manson JE, Kwiatkowski DJ, Liu S. Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies. Am J Hum Genet 2004; 74(2): 208-222.
48. Tsuchiya T, Schwarz PE, Bosque-Plata LD, et al. Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. Mol Genet Metab 2006; 89(1-2): 174-184.
49. Weedon MN, Schwarz PE, Horikawa Y, et al. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am J Hum Genet 2003; 73(5): 1208-1212.
50. Wang Y, Xiang K, Zheng T, Jia W, Shen K, Li J. The UCSNP44 variation of calpain 10 gene on NIDDM1 locus and its impact on plasma glucose levels in type 2 diabetic patients. Zhonghua Yi Xue Za Zhi 2002; 82(9): 613-616.
51. Johnson JD, Han Z, Otani K, et al. RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem 2004; 279(23): 24794-24802.
52. Sreenan SK, Zhou YP, Otani K, et al. Calpains play a role in insulin secretion and action. Diabetes 2001; 50(9): 2013-2020.
53. Zhou YP, Sreenan S, Pan CY, et al. A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. Metabolism 2003; 52(5): 528-534.
54. Ort T, Voronov S, Guo J, et al. Dephosphorylation of β2-syntrophin and Ca2+/mu-calpain-mediated cleavage of ICA512 upon stimulation of insulin secretion. EMBO J 2001; 20(15): 4013-4023.
55. Bowden DW, Sale M, Howard TD, et al. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes 1997; 46(5): 882-886.
56. Ji L, Malecki M, Warram JH, Yang Y, Rich SS, Krolewski AS. New susceptibility locus for NIDDM is localized to human chromosome 20q. Diabetes 1997; 46(5): 876-881.
57. Zouali H, Hani EH, Philippi A, et al. A susceptibility locus for early-onset non-insulin dependent (type 2) diabetes mellitus maps to chromosome 20q, proximal to the phosphoenolpyruvate carboxykinase gene. Hum Mol Genet 1997; 6(9): 1401-1408.
58. Ghosh S, Watanabe RM, Hauser ER, et al. Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. Proc Natl Acad Sci U S A 1999; 96(5): 2198-2203.
59. Silander K, Mohlke KL, Scott LJ, et al. Genetic variation near the hepatocyte nuclear factor-4α gene predicts susceptibility to type 2 diabetes. Diabetes 2004; 53(4): 1141-1149.
60. Hara K, Horikoshi M, Kitazato H, et al. Hepatocyte nuclear factor-4α P2 promoter haplotypes are associated with type 2 diabetes in the Japanese population. Diabetes 2006; 55(5): 1260-1264.
61. Muller YL, Infante AM, Hanson RL, et al. Variants in hepatocyte nuclear factor 4α are modestly associated with type 2 diabetes in Pima Indians. Diabetes 2005; 54(10): 3035-3039.
62. Bagwell AM, Bento JL, Mychaleckyj JC, Freedman BI, Langefeld CD, Bowden DW. Genetic analysis of HNF4α polymorphisms in Caucasian-American type 2 diabetes. Diabetes 2005; 54(4): 1185-1190.
63. Hansen SK, Rose CS, Glumer C, et al. Variation near the hepatocyte nuclear factor (HNF)-4α gene associates with type 2 diabetes in the Danish population. Diabetologia 2005; 48(3): 452-458.
64. Vaxillaire M, Dina C, Lobbens S, et al. Effect of common polymorphisms in the HNF4α promoter on susceptibility to type 2 diabetes in the French Caucasian population. Diabetologia 2005; 48(3): 440-444.
65. Wanic K, Malecki MT, Wolkow PP, et al. Polymorphisms in the gene encoding hepatocyte nuclear factor-4α and susceptibility to type 2 diabetes in a Polish population. Diabetes Metab 2006; 32(1): 86-88.
66. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46(8): 1319-1327.
67. Mukherjee R, Jow L, Croston GE, Paterniti JR Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272(12): 8071-8076.
68. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPAR γ) gene in diabetic Caucasians: identification of a Pro12Ala PPAR γ 2 missense mutation. Biochem Biophys Res Commun 1997; 241(2): 270-274.
69. Celi FS, Shuldiner AR. The role of peroxisome proliferator-activated receptor γ in diabetes and obesity. Curr Diab Rep 2002; 2(2): 179-185.
70. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20(3): 284-287.
71. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268(1): 178-182.
72. Oh EY, Min KM, Chung JH. Significance of Pro12Ala variant in peroxisome proliferator-activated receptor-γ2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000; 85: 1801-1804.
73. Beamer BA, Yen CJ, Andersen RE, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 1998; 47(11): 1806-1808.
74. Meirhaeghe A, Fajas L, Helbecque N, et al. Impact of the peroxisome proliferator activated receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000; 24(2): 195-199.
75. Luan J, Browne PO, Harding AH, et al. Evidence for gene-nutrient interaction at the PPARγ locus. Diabetes 2001; 50(3): 686-689.
76. Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J, Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999; 42(7): 892-895.
77. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR. Genetic variation in the peroxisome proliferator-activated receptor-γ2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 2001; 50(9): 2172-2176.
78. Neel JV. The thrifty genotype revisited. In: Kobberling J, Tattersall R, eds. The Genetics of Diabetes Mellitus. Proceedings of the Serono Symposium. London: Academic Press, 1982: 283-293.
79. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998; 19(4): 379-383.
80. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus. Biochem Biophys Res Commun 1999; 254(2): 450-453.
81. Mancini FP, Vaccaro O, Sabatino L, et al. Pro12Ala substitution in the peroxisome proliferatoractivated receptor-γ2 is not associated with type 2 diabetes. Diabetes 1999; 48(7): 1466-1468.
82. Clement K, Hercberg S, Passinge B, et al. The Pro115Gln and Pro12Ala PPARγ gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000; 24(3): 391-393.
83. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26(1): 76-80.
84. Gonzalez Sanchez JL, Serrano RM, Fernandez PC, Laakso M, Martinez Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002; 147(4): 495-501.
85. Frederiksen L, Brodbaek K, Fenger M, et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-γ gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002; 87(8): 3989-3992.
86. Stumvoll M, Wahl HG, Loblein K, et al. Pro12Ala polymorphism in the peroxisome proliferatoractivated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 2001; 50(4): 876-881.
87. Jacob, et al. Horm Metab Res 2000; 32: 413.
88. Mori Y, Kim-Motoyama H, Katakura T, et al. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor-γ 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998; 251(1): 195-198.
89. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38(3): 320-323.
90. Cauchi S, Meyre D, Choquet H, et al. TCF7L2 variation predicts hyperglycemia incidence in a French general population: the data from an epidemiological study on the insulin resistance syndrome (desir) study. Diabetes 2006; 55(11): 3189-3192.
91. Humphries SE, Gable D, Cooper JA, et al. Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK European whites, Indian Asians and Afro-Caribbean men and women. J Mol Med 2006; 94(12 suppl): 1-10.
92. Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A, et al. Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia 2007; 50(1): 59-62.
93. Damcott CM, Pollin TI, Reinhart LJ, et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006; 55(9): 2654-2659.
94. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet 1999; 23(3): 323-328.
95. Dupont S, Vionnet N, Chevre JC, et al. No evidence of linkage or diabetes-associated mutations in the transcription factors β2/NEUROD1 and PAX4 in Type II diabetes in France. Diabetologia 1999; 42(4): 480-484.
96. Utsunomiya N, Ohagi S, Sanke T, Tatsuta H, Hanabusa T, Nanjo K. Organization of the human carboxypeptidase E gene and molecular scanning for mutations in Japanese subjects with NIDDM or obesity. Diabetologia 1998; 41(6): 701-705.
97. Yagui K, Shimada F, Mimura M, et al. A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with Type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro. Diabetologia 1998; 41(9): 1024-1028.
98. Rau H, Braun J, Donner H, et al. The codon 17 polymorphism of the CTLA4 gene in type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86(2): 653-655.
99. Ristow M, Giannakidou E, Hebinck J, et al. An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin (Friedreich’s ataxia) gene. Diabetes 1998; 47(5): 851-854.
100. Dalgaard LT, Hansen T, Urhammer SA, Clausen JO, Eiberg H, Pedersen O. Intermediate expansions of a GAA repeat in the frataxin gene are not associated with type 2 diabetes or altered glucoseinduced β-cell function in Danish Caucasians. Diabetes 1999; 48(4): 914-917.
101. Hart LM, Ruige JB, Dekker JM, Stehouwer CD, Maassen JA, Heine RJ. Altered β-cell characteristics in impaired glucose tolerant carriers of a GAA trinucleotide repeat polymorphism in the frataxin gene. Diabetes 1999; 48(4): 924-926.
102. Kubota A, Yamada Y, Hayami T, et al. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 1996; 45(12): 1701-1705.
103. Almind K, Ambye L, Urhammer SA, et al. Discovery of amino acid variants in the human glucosedependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic β-cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 1998; 41(10): 1194-1198.
104. Velho G, Froguel P. Genetic determinants of non-insulin-dependent diabetes mellitus: strategies and recent results. Diabetes Metab 1997; 23(1): 7-17.
105. Huang CN, Lee KC, Wu HP, Tai TY, Lin BJ, Chuang LM. Screening for the Gly40Ser mutation in the glucagon receptor gene among patients with type 2 diabetes or essential hypertension in Taiwan. Pancreas 1999; 18(2): 151-155.
106. Lepretre F, Vionnet N, Budhan S, et al. Genetic studies of polymorphisms in ten non-insulindependent diabetes mellitus candidate genes in Tamil Indians from Pondicherry. Diabetes Metab 1998; 24(3): 244-250.
107. Tanizawa Y, Riggs AC, Elbein SC, Whelan A, Donis-Keller H, Permutt MA. Human glucagon-like peptide-1 receptor gene in NIDDM. Identification and use of simple sequence repeat polymorphisms in genetic analysis. Diabetes 1994; 43(6): 752-757.
108. Yagi T, Nishi S, Hinata S, Murakami M, Yoshimi T. A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2, and apolipo protein C-II) with type 2 diabetes and impaired glucose tolerance in Japanese subjects. Diabet Med 1996; 13(10): 902-907.
109. Janssen RC, Bogardus C, Takeda J, Knowler WC, Thompson DB. Linkage analysis of acute insulin secretion with GLUT2 and glucokinase in Pima Indians and the identification of a missense mutation in GLUT2. Diabetes 1994; 43(4): 558-563.
110. Tanizawa Y, Riggs AC, Chiu KC, et al. Variability of the pancreatic islet β-cell/liver (GLUT 2) glucose transporter gene in NIDDM patients. Diabetologia 1994; 37(4): 420-427.
111. Shimada F, Makino H, Iwaoka H, et al. Identification of two novel amino acid polymorphisms in β-cell/liver (GLUT2) glucose transporter in Japanese subjects. Diabetologia 1995; 38(2): 211-215.
112. Matsutani A, Koranyi L, Cox N, Permutt MA. Polymorphisms of GLUT2 and GLUT4 genes. Use in evaluation of genetic susceptibility to NIDDM in blacks. Diabetes 1990; 39(12): 1534-1542.
113. Baroni MG, Oelbaum RS, Pozzilli P, et al. Polymorphisms at the GLUT1 (HepG2) and GLUT4 (muscle/adipocyte) glucose transporter genes and non-insulin-dependent diabetes mellitus (NIDDM). Hum Genet 1992; 88(5): 557-561.
114. Kusari J, Verma US, Buse JB, Henry RR, Olefsky JM. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus. J Clin Invest 1991; 88(4): 1323-1330.
115. Choi WH, O’Rahilly S, Buse JB, et al. Molecular scanning of insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. Diabetes 1991; 40(12): 1712-1718.
116. Groop LC, Kankuri M, Schalin-Jantti C, et al. Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 1993; 328(1): 10-14.
117. Shimomura H, Sanke T, Ueda K, Hanabusa T, Sakagashira S, Nanjo K. A missense mutation of the muscle glycogen synthase gene (M416V) is associated with insulin resistance in the Japanese population. Diabetologia 1997; 40(8): 947-952.
118. Rissanen J, Pihlajamaki J, Heikkinen S, et al. New variants in the glycogen synthase gene (Gln71His, Met416Val) in patients with NIDDM from eastern Finland. Diabetologia 1997; 40(11): 1313-1319.
119. Echwald SM, Bjorbaek C, Hansen T, et al. Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity. Diabetes 1995; 44(3): 347-353.
120. Vidal-Puig A, Printz RL, Stratton IM, Granner DK, Moller DE. Analysis of the hexokinase II gene in subjects with insulin resistance and NIDDM and detection of a Gln142 → His substitution. Diabetes 1995; 44(3): 340-346.
121. Olansky L, Janssen R, Welling C, Permutt MA. Variability of the insulin gene in American blacks with NIDDM. Analysis by single-strand conformational polymorphisms. Diabetes 1992; 41(6): 742-749.
122. Pugliese A, Miceli D. The insulin gene in diabetes. Diabetes Metab Res Rev 2002; 18(1): 13-25.
123. Baier LJ, Sacchettini JC, Knowler WC, et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995; 95(3): 1281-1287.
124. Hayakawa T, Nagai Y, Nohara E, et al. Variation of the fatty acid binding protein 2 gene is not associated with obesity and insulin resistance in Japanese subjects. Metabolism 1999; 48(5): 655-657.
125. Galluzzi JR, Cupples LA, Meigs JB, Wilson PW, Schaefer EJ, Ordovas JM. Association of the Ala54-Thr polymorphism in the intestinal fatty acid-binding protein with 2-h postchallenge insulin levels in the Framingham Offspring Study. Diabetes Care 2001; 24(7): 1161-1166.
126. Yamada K, Yuan X, Ishiyama S, et al. Association between Ala54Thr substitution of the fatty acidbinding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 1997; 40(6): 706-710.
127. Ito K, Nakatani K, Fujii M, et al. Codon 54 polymorphism of the fatty acid binding protein gene and insulin resistance in the Japanese population. Diabet Med 1999; 16(2): 119-124.
128. Rissanen J, Pihlajamaki J, Heikkinen S, Kekalainen P, Kuusisto J, Laakso M. The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes 1997; 46(4): 711-712.
129. Lei HH, Coresh J, Shuldiner AR, Boerwinkle E, Brancati FL. Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 1999; 48(9): 1868-1872.
130. Agren JJ, Valve R, Vidgren H, Laakso M, Uusitupa M. Postprandial lipemic response is modified by the polymorphism at codon 54 of the fatty acid-binding protein 2 gene. Arterioscler Thromb Vasc Biol 1998; 18(10): 1606-1610.
131. Hansen L, Echwald SM, Hansen T, Urhammer SA, Clausen JO, Pedersen O. Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes 1997; 46(3): 508-512.
132. Inoue H, Ferrer J, Warren-Perry M, et al. Sequence variants in the pancreatic islet β-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes 1997; 46(3): 502-507.
133. Sakagashira S, Sanke T, Hanabusa T, et al. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 1996; 45(9): 1279-1281.
134. Yamada K, Yuan X, Ishiyama S, Nonaka K. Glucose tolerance in Japanese subjects with S20G mutation of the amylin gene. Diabetologia 1998; 41(1): 125.
135. Chuang LM, Lee KC, Huang CN, Wu HP, Tai TY, Lin BJ. Role of S20G mutation of amylin gene in insulin secretion, insulin sensitivity, and type II diabetes mellitus in Taiwanese patients. Diabetologia 1998; 41(10): 1250-1251.
136. Birch CL, Fagan LJ, Armstrong MJ, Turnbull DM, Walker M. The S20G islet-associated polypeptide gene mutation in familial NIDDM. Diabetologia 1997; 40(9): 1113.
137. Shimomura H, Sanke T, Hanabusa T, Tsunoda K, Furuta H, Nanjo K. Nonsense mutation of islet-1 gene (Q310X) found in a type 2 diabetic patient with a strong family history. Diabetes 2000; 49(9): 1597-1600.
138. Barat-Houari M, Clement K, Vatin V, et al. Positional candidate gene analysis of Lim domain homeobox gene (Isl-1) on chromosome 5q11-q13 in a French morbidly obese population suggests indication for association with type 2 diabetes. Diabetes 2002; 51(5): 1640-1643.
139. Wolford JK, Hanson RL, Bogardus C, Prochazka M. Analysis of the lamin A/C gene as a candidate for type II diabetes susceptibility in Pima Indians. Diabetologia 2001; 44(6): 779-782.
140. Baier LJ, Wiedrich C, Hanson RL, Bogardus C. Variant in the regulatory subunit of phosphatidylinositol 3-kinase (p85α): preliminary evidence indicates a potential role of this variant in the acute insulin response and type 2 diabetes in Pima women. Diabetes 1998; 47(6): 973-975.
141. Hansen T, Andersen CB, Echwald SM, et al. Identification of a common amino acid polymorphism in the p85α regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes 1997; 46(3): 494-501.
142. Frittitta L, Ercolino T, Bozzali M, et al. A cluster of three single nucleotide polymorphisms in the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes 2001; 50(8): 1952-1955.
143. Pizzuti A, Frittitta L, Argiolas A, et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 1999; 48(9): 1881-1884.
144. Jaikaran ET, Marcon G, Levesque L, George-Hyslop PS, Fraser PE, Clark A. Localisation of presenilin 2 in human and rodent pancreatic islet β-cells; Met239Val presenilin 2 variant is not associated with diabetes in man. J Cell Sci 1999; 112(Pt 13): 2137-2144.
145. Kalidas K, Dow E, Saker PJ, et al. Prohormone convertase 1 in obesity, gestational diabetes mellitus, and NIDDM: no evidence for a major susceptibility role. Diabetes 1998; 47(2): 287-289.
146. Ohagi S, Sakaguchi H, Sanke T, Tatsuta H, Hanabusa T, Nanjo K. Human prohormone convertase 3 gene: exon-intron organization and molecular scanning for mutations in Japanese subjects with NIDDM. Diabetes 1996; 45(7): 897-901.
147. Yoshida H, Ohagi S, Sanke T, Furuta H, Furuta M, Nanjo K. Association of the prohormone convertase 2 gene (PCSK2) on chromosome 20 with NIDDM in Japanese subjects. Diabetes 1995; 44(4): 389-393.
148. Permana PA, Kahn BB, Huppertz C, Mott DM. Functional analyses of amino acid substitutions Arg883Ser and Asp905Tyr of protein phosphatase-1 G-subunit. Mol Genet Metab 2000; 70(2): 151-158.
149. Hansen L, Hansen T, Vestergaard H, et al. A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hum Mol Genet 1995; 4(8): 1313-1320.
150. Xia J, Scherer SW, Cohen PT, et al. A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes. Diabetes 1998; 47(9): 1519-1524.
151. Maegawa H, Shi K, Hidaka H, et al. The 3′-untranslated region polymorphism of the gene for skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1 in the type 2 diabetic Japanese population. Diabetes 1999; 48(7): 1469-1472.
152. Hegele RA, Harris SB, Zinman B, et al. Variation in the AU(AT)-rich element within the 3′-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. J Clin Endocrinol Metab 1998; 83(11): 3980-3983.
153. Prochazka M, Mochizuki H, Baier LJ, Cohen PT, Bogardus C. Molecular and linkage analysis of type-1 protein phosphatase catalytic β-subunit gene: lack of evidence for its major role in insulin resistance in Pima Indians. Diabetologia 1995; 38(4): 461-466.
154. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Analysis of trinucleotide-repeat combination polymorphism at the rad gene in patients with type 2 diabetes mellitus. Metabolism 1999; 48(2): 173-175.
155. Sentinelli F, Romeo S, Arca M, et al. Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002; 51(3): 860-862.
156. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87(6): 2520-2524.
157. Osawa H, Onuma H, Murakami A, et al. Systematic search for single nucleotide polymorphisms in the resistin gene: the absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes 2002; 51(3): 863-866.
158. Varadi A, Lebel L, Hashim Y, Mehta Z, Ashcroft SJ, Turner R. Sequence variants of the sarco(endo)plasmic reticulum Ca(2+)-transport ATPase 3 gene (SERCA3) in Caucasian type II diabetic patients (UK prospective diabetes study 48). Diabetologia 1999; 42(10): 1240-1243.
159. Goksel DL, Fischbach K, Duggirala R, et al. Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Hum Genet 1998; 103(3): 280-285.
160. Hani EH, Clement K, Velho G, et al. Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes 1997; 46(4): 688-694.
161. Baier LJ, Dobberfuhl AM, Pratley RE, Hanson RL, Bogardus C. Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab 1998; 83(8): 2993-2996.
162. Baynes KC, Boucher BJ, Feskens EJ, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997; 40(3): 344-347.
163. Hitman GA, Mannan N, McDermott MF, et al. Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 1998; 47(4): 688-690.
164. Chiu KC, Chuang LM, Yoon C. The vitamin D receptor polymorphism in the translation initiation codon is a risk factor for insulin resistance in glucose tolerant Caucasians. BMC Med Genet 2001; 2: 2.
165. Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical morbidities: results from the cardiovascular health study. Arch Intern Med 2002; 162: 2333-2341.
166. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006; 61(6): 575-584.
167. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17(1): 4-12.
168. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116(7): 1793-1801.
169. de Maat MP, Bladbjerg EM, Hjelmborg JB, Bathum L, Jespersen J, Christensen K. Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 2004; 24(11): 2168-2173.
170. de Craen AJ, Posthuma D, Remarque EJ, van den Biggelaar AH, Westendorp RG, Boomsma DI. Heritability estimates of innate immunity: an extended twin study. Genes Immun 2005; 6(2): 167-170.
171. Achyut BR, Srivastava A, Bhattacharya S, Mittal B. Genetic association of interleukin-1β (-511C/T) and interleukin-1 receptor antagonist (86 bp repeat) polymorphisms with Type 2 diabetes mellitus in North Indians. Clin Chim Acta 2007; 377(1-2): 163-169.
172. Testa R, Olivieri F, Bon AR, et al. Interleukin-6-174 G > C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2006; 71(3): 299-305.
173. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006; 15(11): 1914-1920.
174. Van Houten B, Woshner V, Santos JH. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst) 2006; 5(2): 145-152.
175. Maassen JA, van den Ouweland JM, Hart LM, Lemkes HH. Maternally inherited diabetes and deafness: a diabetic subtype associated with a mutation in mitochondrial DNA. Horm Metab Res 1997; 29(2): 50-55.
176. Donovan LE, Severin NE. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J Clin Endocrinol Metab 2006; 91(12): 4737-4742.
177. Maassen JA, Hart LM, Janssen GM, Reiling E, Romijn JA, Lemkes HH. Mitochondrial diabetes and its lessons for common Type 2 diabetes. Biochem Soc Trans 2006; 34(Pt 5): 819-823.
178. Bhat A, Koul A, Sharma S, et al. The possible role of 10398A and 16189C mtDNA variants in providing susceptibility to T2DM in two North Indian populations: a replicative study. Hum Genet 2007; 120(6): 821-826.
179. Liou CW, Lin TK, Huei WH, et al. A common mitochondrial DNA variant and increased body mass index as associated factors for development of type 2 diabetes: additive effects of genetic and environmental factors. J Clin Endocrinol Metab 2007; 92(1): 235-239.
180. Serman A, Vlahovic M, Serman L, Bulic-Jakus F. DNA methylation as a regulatory mechanism for gene expression in mammals. Coll Antropol 2006; 30(3): 665-671.
181. Schumacher A, Petronis A. Epigenetics of complex diseases: from general theory to laboratory experiments. Curr Top Microbiol Immunol 2006; 310: 81-115.
182. Crews D, McLachlan JA. Epigenetics, evolution, endocrine disruption, health, and disease. Endocrinology 2006; 147(6 suppl): S4-S10.
183. Vanden Berghe W, Ndlovu MN, Hoya-Arias R, Dijsselbloem N, Gerlo S, Haegeman G. Keeping up NF-kappaB appearances: epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol 2006; 72(9): 1114-1131.
184. Bjornsson HT, Fallin MD, Feinberg AP. An integrated epigenetic and genetic approach to common human disease. Trends Genet 2004; 20(8): 350-358.
185. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
186. Rincon-Choles H, Thameem F, Lehman DM, et al. Genetic basis of diabetic nephropathy. Am J Ther 2005; 12(6): 555-561.
187. Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes 2006; 114(6): 275-294.
188. Rietveld I, Ikram MK, Vingerling JR, et al. An IGF-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 2006; 55(8): 2387-2391.
189. Ng DP, Warram JH, Krolewski AS. TGF-β 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. Am J Kidney Dis 2003; 41(1): 22-28.
190. Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. Diabetes 1998; 47(7): 1164-1169.
191. McKnight AJ, Maxwell AP, Sawcer S, et al. A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. J Am Soc Nephrol 2006; 17(3): 831-836.